New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
17:36 EDTOGXIOncoGenex sees having enough funds for operations into Q315
From April 1 through the date of this Current Report on Form 8-K, OncoGenex Pharmaceuticals has offered and sold 809,214 shares of its common stock pursuant to its At-the-Market Issuance Sales Agreement with MLV & Co. LLC. These sales resulted in net proceeds to the company of approximately $2.9M. Prior to these sales, the company had not made any sales under this “at the market” equity offering program, and, as the date of this Current Report on Form 8-K, shares of the company’s common stock having an aggregate value of approximately $22M remained available for sale under this offering program. Based on the company’s current expectations and operating plans, and before giving effect to the receipt of net proceeds from its proposed offering of securities, the company believes that its cash, cash equivalents, short-term investments and receivables from its collaboration arrangement with Teva will be sufficient to fund its current planned operations into the third quarter of 2015.
News For OGXI From The Last 14 Days
Check below for free stories on OGXI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
06:32 EDTOGXIOncoGenex completes patient enrollment in Phase 3 AFFINITY trial
OncoGenex Pharmaceuticals announced that patient enrollment has been completed in the Phase 3 AFFINITY trial. The international, randomized, open-label Phase 3 AFFINITY trial is designed to evaluate the potential of custirsen to improve survival outcomes in approximately 630 men with metastatic castrate-resistant prostate cancer. Patients have been randomized to receive second-line Jevtana and prednisone with or without custirsen.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use